Adamas Pharmaceuticals Inc (NASDAQ:ADMS) COO Richard King sold 2,501 shares of Adamas Pharmaceuticals stock in a transaction dated Thursday, June 21st. The stock was sold at an average price of $25.48, for a total value of $63,725.48. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Adamas Pharmaceuticals opened at $25.21 on Monday, MarketBeat.com reports. Adamas Pharmaceuticals Inc has a 1-year low of $13.50 and a 1-year high of $44.00. The company has a debt-to-equity ratio of 0.63, a current ratio of 9.85 and a quick ratio of 9.73. The stock has a market capitalization of $680.22 million, a PE ratio of -6.35 and a beta of 1.51.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its earnings results on Thursday, May 3rd. The specialty pharmaceutical company reported ($1.35) EPS for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.02. Adamas Pharmaceuticals had a negative return on equity of 101.94% and a negative net margin of 3,470.97%. The business had revenue of $2.55 million during the quarter, compared to analyst estimates of $1.71 million. analysts expect that Adamas Pharmaceuticals Inc will post -5.79 earnings per share for the current year.
A number of institutional investors have recently modified their holdings of ADMS. Sei Investments Co. increased its position in Adamas Pharmaceuticals by 49.8% in the 1st quarter. Sei Investments Co. now owns 7,627 shares of the specialty pharmaceutical company’s stock valued at $182,000 after buying an additional 2,536 shares in the last quarter. Granite Springs Asset Management LLC bought a new stake in Adamas Pharmaceuticals in the 4th quarter valued at about $207,000. DekaBank Deutsche Girozentrale bought a new stake in Adamas Pharmaceuticals in the 1st quarter valued at about $227,000. MetLife Investment Advisors LLC bought a new stake in Adamas Pharmaceuticals in the 4th quarter valued at about $239,000. Finally, Barclays PLC increased its position in Adamas Pharmaceuticals by 392.7% in the 1st quarter. Barclays PLC now owns 11,692 shares of the specialty pharmaceutical company’s stock valued at $279,000 after buying an additional 9,319 shares in the last quarter. 91.64% of the stock is owned by institutional investors and hedge funds.
Several research analysts have recently weighed in on ADMS shares. Needham & Company LLC set a $40.00 price objective on Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, February 25th. Zacks Investment Research raised Adamas Pharmaceuticals from a “sell” rating to a “buy” rating and set a $35.00 price objective for the company in a research report on Tuesday, May 8th. Mizuho reissued a “buy” rating and issued a $49.00 price objective on shares of Adamas Pharmaceuticals in a research report on Friday, April 20th. BidaskClub raised Adamas Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, May 1st. Finally, Piper Jaffray Companies set a $49.00 price objective on Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, April 22nd. One investment analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $42.11.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.